Oxford BioDynamics PLC - Oxford-based biotechnology firm focused on discovery and development of epigenetic biomarkers - Plans acceleration of final development and launch of PSE clinical test in both the UK and US, for availability in the fourth quarter. Commences certification of clinical testing facility within existing Oxford base. Reports the EpiSwitch CiRT blood test continues to gain traction in the US, posting record monthly orders in November and December 2022, and January and March 2023. Adds uptake of the test is growing, through both new and repeat orders. Intends to present both tests in a key note address at the 13th World Clinical Biomarker & Companion Diagnostics Europe Summit.

Current stock price: 16.14 pence

12-month change: down 0.5%

Copyright 2023 Alliance News Ltd. All Rights Reserved.